ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ONG Oxford Nutra Gp

4.00
0.00 (0.00%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Nutra Gp LSE:ONG London Ordinary Share GB00B3LXPB43 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Development Agreement

12/04/2010 7:00am

RNS Non-Regulatory



 

TIDMONG 
 
 
Oxford Nutrascience Group PLC 
12 April 2010 
 
? 
 
12 April 2010 
    Agreement signed to establish manufacturing capability for Chewitab(TM) 
Oxford Nutrascience Group plc ("Oxford Nutrascience" or "the Company") announces 
that it has signed a development agreement with Surepharm Services Limited to 
scale-up and validate manufacturing processes for its Chewitab(TM) delivery 
systems. 
Chewitab(TM) is the Company's brand name for its chewable tablet for vitamins 
and medicines. Prototypes produced by Oxford Nutrascience have performed well 
and under the terms of the agreement Surepharm will be responsible for 
demonstrating the manufacturing processes as the Company moves towards the 
commercialisation of its Chewitab(TM) products. 
Oxford Nutrascience intends to launch Chewitab(TM) products including a chewable 
calcium supplement and a chewable multi-vitamin supplement as well as license 
the technology to over-the-counter consumer healthcare companies. 
Nigel Theobald, Chief Executive, Oxford Nutrascience Group Plc commented: 
"The performance of the Chewitab prototypes in our laboratories has been 
excellent and prototypes have been well received by a number of major consumer 
healthcare companies in several markets around the world. 
"By working closely with our development partners, Oxford Nutrascience is now 
ready to move to its next phase and demonstrate that our products can be 
produced on a mass scale. 
"The signing of this development agreement is an important step towards the use 
of our technology in making self medication easier. Initial interest is already 
being shown by a number of the major brand owners in the consumer healthcare 
pharmaceutical sectors to license our technology." 
                                    - Ends - 
For further information: 
www.oxfordnutrascience.com 
 
Oxford Nutrascience Group Plc 
Nigel Theobald, Chief Executive                           +44 1865 854874 
Mark Way, Investor and Media Relations              +44 7786 116991 
 
ZAI Corporate Finance (Nominated Adviser) 
John Depasquale                                               +44 20 7060 2220 
Sarang Shah                                                     +44 20 7060 2220 
About Oxford Nutrascience Group Plc 
·      Oxford Nutrascience is a UK consumer healthcare company that develops 
chewy confectionery, chewable tablets and liquid suspensions to allow medicines 
and vitamin supplements to be taken in a more pleasant and convenient way. 
 
·      Oxford Nutrascience has developed technology for the use of prebiotic 
soluble fibres in medicine delivery systems that disperse and solubilise 
medicines, improve taste and mouth feel, simplify processing and eliminate 
additives, incorporate prebiotic health benefits. 
 
·      Chews: Oxford Nutrascience currently produces Ellactiva , a calcium chewy 
supplement sold in the UK and in the Middle East, and plans to launch new chews 
to complement this existing product. 
 
·      Chewable tablets and liquid suspensions: The target market for Oxford 
Nutrasciences' Chewitabs(TM) and liquid suspension delivery systems are 
over-the-counter ("OTC") pain relieving drugs, indigestion preparations and 
cough and cold medicines. 
 
·      Oxford Nutrascience's medicine development work is currently focused on 
ibuprofen suspension and chewable allergy tablets incorporating loratadine. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAILMITMBAMBPM 
 

1 Year Oxford Nutrascience Chart

1 Year Oxford Nutrascience Chart

1 Month Oxford Nutrascience Chart

1 Month Oxford Nutrascience Chart